Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder

Journal of Psychiatric Research

Volumn 46, Issue 10, 2012, Pages 1333-1338

  Power, Robert A ^a   Muthén, Bengt ^b   Henigsberg, Neven ^c   Mors, Ole ^d   Placentino, Anna ^e,f,g   Mendlewicz, Julien ^h   Maier, Wolfgang ⁱ   McGuffin, Peter ^a   Lewis, Cathryn M ^a   Uher, Rudolf ^a,j  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d AARHUS UNIVERSITY   (Denmark)

^e Department of Mental Health   (Italy)

^f IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

^h FREE UNIVERSITY OF BRUSSELS   (Belgium)

ⁱ UNIVERSITY OF BONN   (Germany)

^j DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

Antidepressant medication; Depression; Dropout; Randomized controlled trials

Indexed keywords

ESCITALOPRAM; NORTRIPTYLINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NONRANDOM DISTRIBUTION OF MISSING OUTCOME; NONRANDOM DROPOUT; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; BAYES THEOREM; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; MODELS, STATISTICAL; NORTRIPTYLINE; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 84865536486     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.06.014     Document Type: Article

References (21)

1. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2008, 22:343-396.
2. Arroll B., Macgillivray S., Ogston S., Reid I., Sullivan F., Williams B., et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Annals of Family Medicine 2005, 3:449-456.
3. Gueorguieva R., Mallinckrodt C., Krystal J.H. Trajectories of depression severity in clinical trials of duloxetine insights into antidepressant and placebo responses. Archives of General Psychiatry 2011, 68:1227-1237.
4. Hirschfeld R.M.A. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Journal of Clinical Psychiatry 1999, 60:326-335.
5. Lingam R., Scott J. Treatment non-adherence in affective disorders. Acta Psychiatrica Scandinavica 2002, 105:164-172.
6. Little R.J.A. Modeling the drop-out mechanism in repeated-measures studies. Journal of the American Statistical Association 1995, 90:1112-1121.
7. Little R.J.A., Rubin M.B. Statistical analysis with missing data 2002, Wiley-Interscience, New York. 2nd ed.
8. MacGillivray S., Arroll B., Hatcher S., Ogston S., Reid I., Sullivan F., et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. British Medical Journal 2003, 326:1014-1017.
9. Marques T.R., Arenovich T., Agid O., Sajeev G., Muthen B., Chen L., et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychological Medicine 2011, 41:1481-1488.
10. Muthén B., Asparouhov T., Hunter A.M., Leuchter A.F. Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial. Psychological Methods 2011, 16:17-33.
11. Muthén B., Brown C.H., Masyn K., Jo B., Khoo S.T., Yang C.C., et al. General growth mixture modeling for randomized preventive interventions. Biostatistics 2002, 3:459-475.
12. Muthén B.O. Mplus user's guide 2010, Muthén & Muthén, Los Angeles, CA. 6th ed.
13. Olfson M., Marcus S.C., Tedeschi M., Wan G.J. Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry 2006, 163:101-108.
14. Roy J. Modeling longitudinal data with nonignorable dropouts using a latent dropout class model. Biometrics 2003, 59:829-836.
15. Stauffer V., Case M., Kollack-Walker S., Ascher-Svanum H., Ball T., Kapur S., et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophrenia Research 2011, 130:11-19.
16. Uher R., Farmer A., Maier W., Rietschel M., Hauser J., Marusic A., et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine 2008, 38:289-300.
17. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., Mors O., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal 2009, 9:225-233.
18. Uher R., Maier W., Hauser J., Marusic A., Schmael C., Mors O., et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry 2009, 194:252-259.
19. Uher R., Mors O., Rietschel M., Rajewska-Rager A., Petrovic A., Zobel A., et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of Clinical Psychiatry 2011, 72:1478-1484.
20. Uher R., Muthen B., Souery D., Mors O., Jaracz J., Placentino A., et al. Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine 2010, 40:1367-1377.
21. Uher R., Perroud N., Ng M.Y.M., Hauser J., Henigsberg N., Maier W., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry 2010, 167:555-564.